Zanaflex
In brief
- In our pharmacy, you can buy Zanaflex without a prescription, with delivery across the United Kingdom in 9–21 days and discreet packaging.
- Zanaflex (tizanidine) is used to relieve muscle spasticity (for example in multiple sclerosis or spinal cord injury); it is a centrally acting alpha‑2 adrenergic agonist that reduces spasticity by inhibiting presynaptic motor neurone activity and decreasing excitatory neurotransmitter release.
- The usual dose is to start at 2 mg up to three times daily, titrating by 2–4 mg every 4–7 days as needed; the typical maximum recommended dose is 36 mg per day.
- Administration is oral, as tablets (2 mg and 4 mg).
- The effect typically begins within about 30–60 minutes, with peak effects around 1–2 hours after dosing.
- Duration of action is short‑acting, usually around 3–6 hours, so multiple daily doses are often required.
- Do not consume alcohol — alcohol increases sedation, dizziness and the risk of low blood pressure and respiratory depression when combined with Zanaflex.
- The most common side effect is drowsiness (other frequent effects include dry mouth, dizziness, weakness and hypotension).
- Would you like to try Zanaflex without a prescription?
Basic Zanaflex information
- INN (international nonproprietary name): Tizanidine.
- Brand names available in the United Kingdom: Zanaflex; generic tizanidine.
- ATC code: M03BX02.
- Forms and dosages: Tablets 2 mg and 4 mg.
- Manufacturers in the United Kingdom: generic suppliers including Accord Healthcare, Apotex, Teva and Mylan.
- Registration status in the United Kingdom: Licensed by the MHRA; prescription-only medicine (POM).
- OTC / Rx classification: Prescription-only medicine (POM) — not OTC.
Critical warnings, restrictions and patient protection (UK focus)
Safety-first summary for clinicians, pharmacists and patients
Tizanidine is a prescription-only medicine and must be treated as such in routine UK practice.
Avoid concomitant use of fluvoxamine or ciprofloxacin because these are absolute contraindications due to large rises in tizanidine exposure and severe hypotension and sedation.
Screen for hepatic impairment before starting tizanidine and use extreme caution in patients with liver disease because the drug is metabolised in the liver.
Warn patients about hypotension, sedation and bradycardia as immediate safety priorities.
Report suspected adverse reactions and drug interactions to the MHRA Yellow Card scheme.
Pharmacists should confirm any MHRA safety alerts and consult the product SPC before supply.
In community practice, check electronic prescriptions, confirm allergy and pregnancy status, and run interaction checks on the patient medication record (PMR).
Counsel carers and occupational safety teams when patients work at height or operate machinery because drowsiness and dizziness are common.
Pre-supply checklist
- Valid prescription sighted and indication documented.
- Allergy status and pregnancy/breastfeeding screening completed.
- Medication review for interactions (notably fluvoxamine, ciprofloxacin, other CNS depressants, antihypertensives).
- Baseline blood pressure and heart rate recorded where appropriate.
- Liver function tests (LFTs) available if patient has known liver disease.
- Patient counselled on sedation, driving and workplace safety; counselling recorded on PMR.
Immediate contraindications
- Concomitant fluvoxamine.
- Concomitant ciprofloxacin.
- Known allergy to tizanidine or excipients.
- Severe hepatic impairment.
| Yellow Card reporting steps | Practical action |
|---|---|
| Step 1 | Collect patient details, medicine name and batch if available. |
| Step 2 | Report suspected adverse reaction via the MHRA Yellow Card online form or app. |
| Step 3 | Document the report and notify the prescriber where relevant. |
High-risk groups (elderly, pregnancy, chronic illness)
Which patients need extra care?
Elderly, pregnant or breastfeeding patients, people with liver disease, and patients with multiple medicines are higher risk groups for tizanidine adverse effects.
High-risk features
- Age over 65 with polypharmacy or frailty.
- Known hepatic impairment or raised liver enzymes.
- Concurrent use of antihypertensives, beta-blockers or other CNS depressants.
- Pregnancy or breastfeeding where safety data are limited.
Monitoring schedule checklist
- Baseline BP and heart rate before starting, then within 1–2 weeks of initiation or dose change.
- Liver function tests before starting if risk factors present, then periodically per local protocol.
- Medication review within 1–2 weeks of initiation to check tolerability and interactions.
- Document monitoring plan in the GP record and flag on PMR for community pharmacy review.
Interaction with activities (driving, workplace safety under UK law)
Tizanidine commonly causes drowsiness and dizziness and patients must understand the risks to driving and safety-critical work.
Advise patients that UK drivers are legally required to ensure medicines do not impair their ability to drive.
Advise checking the DVLA guidance and contacting occupational health for safety-critical roles such as HGV drivers, pilots and rail staff.
Provide written advice and record counselling on the PMR.
Consider dosing times to avoid taking doses before shifts and recommend workplace adjustments like avoiding lone working at heights.
Q&A — “Can I drive after taking it in the UK?”
Q: Can I drive after taking tizanidine?
A: No definitive guarantee can be given; if you feel drowsy, dizzy or unsteady you must not drive.
Check DVLA guidance and discuss with the prescriber; avoid driving until individual tolerability is established.
Practical driving and workplace advice
- Do not drive or operate machinery until you know how tizanidine affects you.
- Avoid alcohol and other sedatives when taking tizanidine.
- Schedule first doses at times when rest is possible if sedation occurs.
- Inform employer and occupational health if in a safety-critical job.
When to restrict driving checklist
- Any episode of excessive drowsiness, dizziness or fainting.
- When dose changes are pending and tolerability is unknown.
- If combined with other CNS depressants or antihypertensives causing impairment.
Usage basics: names, classification and legal status
INN, brand names available and classification
What is tizanidine called and how is it classified?
Tizanidine is the International Nonproprietary Name (INN) for this centrally acting muscle relaxant.
In the UK, it is available as Zanaflex and as generic tizanidine tablets in 2 mg and 4 mg strengths.
The ATC code is M03BX02 and the classification is skeletal muscle relaxants, other centrally acting agents.
- INN
- Tizanidine.
- ATC
- M03BX02.
- Classification
- Centrally acting skeletal muscle relaxant (alpha-2 adrenergic agonist).
- Brand/form variants: Zanaflex tablets; generic tizanidine tablets.
- Dosage forms: Tablets 2 mg and 4 mg.
Legal classification and NHS context
How is tizanidine handled in the UK health system?
Tizanidine is a prescription-only medicine (POM) in the UK and must be supplied only with a valid NHS or private prescription.
Pharmacists must verify identity, confirm indication and document supply on the PMR.
- Pharmacy verification steps: Check prescription validity, confirm identity, screen interactions on PMR, document supply and counselling.
Dosing guide (practical NHS-focused approach)
Standard regimens and titration
How should tizanidine be started and adjusted?
Start at 2 mg one to three times daily and increase by 2–4 mg every 4–7 days according to response and tolerability.
The maximum reported daily dose is 36 mg per day.
Short-term targeted dosing around physiotherapy sessions may be used to improve participation.
Always consult the SPC and document a clear titration plan with review within 1–2 weeks of initiation or dose change.
- Titration steps checklist: Start low at 2 mg; increase by 2–4 mg every 4–7 days; review BP/HR and sedation after each change; stop or reduce if intolerable adverse effects occur.
- Dose-limiting side effects: Drowsiness, hypotension, bradycardia, severe dizziness, excessive weakness.
Adjustments for comorbidities (liver, renal, elderly)
Who needs dose changes?
Use extreme caution in liver impairment because tizanidine is metabolised hepatically and monitor LFTs closely.
For renal impairment, consider lower doses and closer monitoring for toxicity.
Elderly patients should start at the lowest dose and titrate slowly because of increased risk of orthostatic hypotension and sedation.
Coordinate dosing changes with the patient’s GP and add alerts on the pharmacy PMR to avoid accidental prescribing errors.
Q&A — “What if I miss a dose?”
Q: What if I miss a dose of tizanidine?
A: Take the missed dose as soon as you remember unless it is close to the next scheduled dose; do not double the dose.
- When to contact services: If you have taken too much, experience excessive drowsiness, breathing difficulty or fainting, seek immediate medical help.
Interaction chart and important drug conflicts
Food, drink and lifestyle interactions
What lifestyle factors affect tizanidine?
Alcohol and other central nervous system depressants potentiate sedation and can increase risk of respiratory depression.
Caffeine may counteract sedation unpredictably but is not a direct pharmacokinetic interaction.
Follow the SPC for advice on timing relative to food, as different formulations and food can alter absorption.
- Do: Avoid alcohol while taking tizanidine.
- Do: Keep dosing consistent in relation to meals as advised by prescriber.
- Don’t: Mix with sedatives, excessive alcohol or new prescription opioids without review.
| Substance | Effect |
|---|---|
| Alcohol | Increased sedation and respiratory depression. |
| Benzodiazepines / opioids | Potentiation of sedation and risk of respiratory compromise. |
Major drug conflicts
Which drugs are the most dangerous to combine with tizanidine?
Strong CYP1A2 inhibitors are major conflicts — fluvoxamine and ciprofloxacin are absolute contraindications.
Other relevant interactions include other antihypertensives, beta-blockers and any CNS depressant such as opioids or benzodiazepines.
Report suspected adverse interactions to the MHRA Yellow Card and instruct patients to bring all medicines including OTC and herbal remedies to reviews.
| Drug | Interaction | Clinical action |
|---|---|---|
| Fluvoxamine | Strong CYP1A2 inhibitor; marked increase in tizanidine levels. | Contraindicated — do not co-prescribe. |
| Ciprofloxacin | Strong CYP1A2 inhibitor; severe hypotension and sedation reported. | Contraindicated — alternative antibiotic should be used. |
| Opioids / benzodiazepines | Increased sedation and respiratory depression. | Review need for combined CNS depressants; warn patient and monitor closely. |
- Reporting steps: Document the interaction, advise the prescriber, and submit a Yellow Card if an adverse event occurred.
Legal status and availability in the UK
In our online pharmacy, Zanaflex is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Mechanism of action and pharmacology (plain-language and clinical)
Simplified explanation for patients
What does tizanidine do in simple terms?
Tizanidine is a centrally acting alpha-2 adrenergic agonist that reduces spasticity by increasing inhibition of motor neurones in the spinal cord.
It treats the symptom of spasticity and is used to improve comfort and mobility, commonly alongside physiotherapy.
- Mechanism
- Alpha-2 adrenergic agonist reducing presynaptic excitatory transmission.
- Patient expectation
- Reduced muscle spasms, possible increased ability to take part in physiotherapy, and side effects such as drowsiness.
- What patients can expect: Some relief within days of titration; full benefit may take weeks; sedation may limit daytime activities.
Clinical pharmacology for clinicians
What are the key PK/PD points clinicians should remember?
Oral absorption varies by formulation and tizanidine is metabolised predominantly in the liver, so accumulation can occur in hepatic impairment.
Its pharmacodynamic profile includes sedation and hypotension, and it is metabolised via CYP pathways, notably CYP1A2 interactions are clinically important.
When switching formulations, monitor for bioequivalence differences and adjust monitoring as needed.
- PK/PD points: Hepatic metabolism, variable absorption by formulation, sedation and hypotension as dose-limiting effects.
| Formulation | Clinical note |
|---|---|
| Tablets (2 mg, 4 mg) | Standard oral dosing; follow SPC for food effects. |
Indications and off-label uses in NHS practice
MHRA-approved indications and common NHS uses
What is the licensed use of tizanidine?
Primary licensed indication is for symptomatic treatment of spasticity associated with multiple sclerosis or spinal cord injury.
In NHS practice, clinicians should follow the SPC and local formularies and document the indication clearly on the prescription.
- Approved indications: Spasticity related to multiple sclerosis and spinal cord injury.
- Documentation checklist: Record indication on the prescription, include monitoring arrangements and advise on follow-up with GP or physiotherapy team.
Off-label practices and when they may be used
When might clinicians prescribe tizanidine off-label?
Off-label use may include significant spasm from other neurological causes or short-term use for acute musculoskeletal spasm when alternatives are unsuitable.
Off-label prescribing must be justified in the medical record and discussed with the patient with documented consent.
- Off-label scenarios: Focal spasm not covered by licence; short-term adjunct for physiotherapy when other agents are unsuitable.
- Off-label governance
- Document rationale, discuss risks and benefits, obtain informed consent and plan monitoring.
Alternatives matrix (NHS prescribing alternatives)
Comparison table
| Drug | Pros | Cons | Typical NHS place in therapy |
|---|---|---|---|
| Tizanidine | Useful for spasticity; short targeted dosing around therapy. | Sedation, hypotension, important CYP1A2 interactions. | Option for MS/spinal injury when monitored closely. |
| Baclofen | Effective antispastic agent; intrathecal option for severe cases. | Can cause sedation and weakness; withdrawal risk with abrupt stop. | First-line oral option in many local formularies. |
| Diazepam | Rapid onset for acute spasm; muscle relaxant and anxiolytic effects. | Sedation, dependence risk. | Short-term adjunct for acute severe spasm. |
- Checklist when to choose an alternative: History of hepatic disease, contraindicated interactions, intolerable sedation, or lack of benefit after a monitored trial.
Pros and cons checklist (patient-facing)
- Benefits: Reduced spasm, potential to improve physiotherapy tolerance and comfort.
- Risks: Drowsiness, dry mouth, low blood pressure, drug interactions.
- Practicalities: Prescription-only, monitoring for BP and LFTs as required, avoid fluvoxamine and ciprofloxacin.
- Monitoring priorities: BP/HR checks, LFTs in patients with liver risk factors, review of concurrent CNS depressants.
Common patient questions
Which questions do people ask most often in consultations?
- How quickly does it work? — Benefits may be apparent within days of titration but full effect often takes weeks.
- What are common side effects? — Drowsiness, dry mouth, dizziness and hypotension are common; report severe symptoms promptly.
- Can I stop suddenly? — No; do not stop abruptly because rebound hypertension or withdrawal effects can occur; taper under clinical supervision.
- Is it safe with other pain meds? — Use caution with opioids and benzodiazepines; review interactions before combining therapies.
When to call GP or emergency services checklist
- Any signs of severe drowsiness, breathing difficulty or fainting — call 999.
- New unexplained chest pain, severe bradycardia or collapse — emergency care required.
- Worsening liver symptoms (jaundice, dark urine) — contact GP urgently.
Registration and regulation (MHRA and NHS frameworks)
MHRA approval and SPC adherence
Always consult the SPC for the licensed product before prescribing or dispensing.
Report adverse reactions using the MHRA Yellow Card scheme and follow MHRA safety communications for updates on interactions or manufacturing issues.
Local NHS formularies or trust guidelines may impose additional restrictions.
- Regulatory steps: Check SPC, verify licence status, adhere to MHRA safety notices and document adverse events.
SPC checks before prescribing checklist
- Confirm licensed indication and dosing limits.
- Check contraindications and interaction warnings.
- Verify special population guidance (elderly, hepatic impairment).
Prescribing framework within NHS
Use NHS clinical governance when prescribing tizanidine.
Document indication, monitoring plans (BP, LFTs) and informed consent for off-label use.
Use EPS for repeats and ensure the PMR includes monitoring and interaction alerts.
If prescribing privately, provide clear written instructions and coordinate follow-up with the patient’s GP.
- Prescribing record template checklist: Indication, start date, titration plan, monitoring schedule, review date, prescriber contact.
- Key governance terms
- Informed consent, SPC adherence, Yellow Card reporting, PMR documentation, shared-care arrangements.
Storage, handling and UK household guidance
Storage and transport (practical tips)
How should tizanidine be stored at home and during travel?
Store at controlled room temperature 20–25°C and protect from moisture and light.
Keep medication in the original packaging and out of reach of children.
Avoid storing in bathrooms or other damp areas and do not freeze the product.
When travelling, carry medicines in the original container with prescription details to avoid customs issues.
- Home storage checklist: Store 20–25°C, protect from moisture, keep original packaging, out of reach of children.
- Travel tips: Carry prescription, avoid leaving medicine in a hot car, pack in hand luggage for air travel.
Handling, disposal and overdose advice
How to dispose of unused tizanidine and what to do in overdose?
Return unused medicines to a community pharmacy for safe disposal via the NHS take-back service.
In overdose, seek immediate emergency care; symptoms may include severe drowsiness, bradycardia and respiratory depression.
Pharmacists should supply a patient information leaflet and document counselling on disposal and overdose actions.
- Disposal steps: Do not flush; return to pharmacy; ask staff about local take-back arrangements.
- Overdose actions checklist: Call 999 for severe symptoms; take medication packaging to the emergency department; report incident to prescriber and consider Yellow Card if relevant.
Guidelines for proper use and pharmacist counselling style
Structured counselling checklist for UK pharmacists
What should pharmacists cover when counselling patients starting tizanidine?
Adopt a structured approach: verify identity and indication, review all medicines including OTC and herbal, warn about driving and alcohol, explain titration and missed-dose rules, discuss monitoring and arrange follow-up.
Provide a written dosing schedule and record counselling on the PMR.
Escalate concerns to the prescriber for significant interactions or adverse effects and document Yellow Card reports where appropriate.
- Counselling steps checklist: Verify prescription; discuss dosing and titration; warn about interactions and driving; advise on monitoring; provide written instructions; record on PMR.
- Short patient leaflet summary
- Take as directed. Do not mix with alcohol. Expect possible drowsiness. Do not drive until you know how it affects you. Keep out of reach of children. Contact your pharmacist or GP with concerns.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | England | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Liverpool | England | 9–21 days |
| Bristol | England | 9–21 days |
| Newcastle Upon Tyne | England | 9–21 days |
| Sheffield | England | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Nottingham | England | 9–21 days |
Final note.
Tizanidine is a useful option for selected patients with spasticity when prescribed and monitored carefully in line with the SPC and MHRA guidance.
Pharmacists should maintain a safety-first counselling style, document supplies and report adverse events via Yellow Card as needed.